Brief: Delcath Systems Announces FDA Approval Of HEPZATO KIT for The Treatment Of Adult Patients With Unresectable Hepatic-Dominant Metastatic Uveal Melanoma
15/08/2023 02:13
Aug 14 (Reuters) - Delcath Systems Inc DCTH.O :
* DELCATH SYSTEMS, INC. ANNOUNCES FDA APPROVAL OF HEPZATO
KIT™ FOR
THE TREATMENT OF ADULT PATIENTS WITH UNRESECTABLE
HEPATIC-DOMINANT METASTATIC UVEAL MELANOMA
* : APPROVAL INCLUDES TREATMENT NAÏVE AND PREVIOUSLY TREATED
PATIENTS AND IS NOT LIMITED BY HLA GENOTYPE
* CO PLANS TO HAVE COMMERCIAL PRODUCT AVAILABLE IN Q4
Source text for Eikon: ID:nPncgsRpga
Further company coverage: DCTH.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Delcath Systems
See all newsBrief: Delcath Systems Highlights Clinical Program Presentations At Esmo Congress 2026 And Independent Data On Percutaneous Hepatic Perfusion In Liver-Dominant Metastatic Uveal Melanoma
Brief: Delcath Systems Announces Inducement Grants Under Nasdaq Listing Rule
Delcath Systems Inc reports results for the quarter ended June 30 - Earnings Summary
Delcath Systems Q2 revenue rises, beats estimates
Delcath Systems Inc expected to post a loss of 9 cents a share - Earnings Preview